Researchers create stem cell model to identify potential targeted epilepsy treatment

In a new study published in the scientific journal Brain, researchers at Children’s Hospital of Philadelphia have used…

Read more
04 Dec 2023

Extra bolagsstämma

Aktieägarna i Fluicell AB (publ), org.nr 556889-3282, kallas härmed till extra bolagsstämma torsdagen den 4 januari 2024 kl….

Read more
30 Nov 2023

Fluicell publishes 2023 Q3 Interim report

Today, August 2023, Fluicell publishes the financial report for the period January 1 to June 30, 2023. The…

Read more
30 Nov 2023

Fluicell at ATMP Sweden 2023

Building a strong community that contains therapeutic developers, healthcare organizations, and infrastructure and service providers is essential for…

Read more
27 Nov 2023

The shape of medicine to come – Presentation with CEO Carolina Trkulja

Did you miss the presentation last week by CEO Carolina Trkulja on how Fluicell is transforming how we…

Read more
09 Nov 2023

Fluicell CEO Newsletter 03, 2023

“I see great potential in our technology, and I think we have only scratched the surface of what…

Read more
26 Oct 2023

A Fluicell ready to address future health challenges

Over the past year, Fluicell has made significant progress in the development of bioprinted tissue-based products for therapeutic…

Read more
24 Oct 2023

Non-animal research models workshop

Tomorrow, we have the honor of hosting a workshop on non-animal models in research and drug development, featuring…

Read more
17 Oct 2023

Bioprinted cancer models using de-cellularized tumors

Faithfully replicating the tumor microenvironment is critical for understanding cancer development. In our new application note In our…

Read more
02 Oct 2023